The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences.
about
Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology PerspectiveAntinociceptive Effects of Prim-O-Glucosylcimifugin in Inflammatory Nociception via Reducing Spinal COX-2.Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study.Advances in use of immunomodulatory agents--a rheumatology perspective.Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences.Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.Bococizumab for the treatment of hypercholesterolaemia.Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid ArthritisPreexisting Antibodies to an F(ab')2 Antibody Therapeutic and Novel Method for Immunogenicity Assessment.Suppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptide.Sustained secretion of anti-tumor necrosis factor α monoclonal antibody from ex vivo genetically engineered dermal tissue demonstrates therapeutic activity in mouse model of rheumatoid arthritis.Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.The importance of handling high-value biologicals: Physico-chemical instability and immunogenicity of monoclonal antibodies.Etanercept, Adalimumab und Ustekinumab bei Psoriasis: Analyse von 209 Behandlungsreihen in Österreich.
P2860
Q36653930-87B0C308-D223-4EA2-8A40-2ACB18EC3D88Q37058928-02B0B9E5-0541-4B33-BC1E-A74D65CCA661Q37394520-7D4BC61C-07D9-426A-A6C9-700B2700B461Q37453033-4C630B78-2861-404C-9A2A-1C8C68E78B51Q38431512-80666644-7066-4238-A3BA-CC57B1D4BC51Q38673326-9E3E65FE-CDDE-4CE0-85F8-55A718D3EBCAQ38898145-00AB32FF-EA1F-4058-97B2-344EBC6278E5Q38940190-40FDCDCE-67F8-4924-A33A-9FC295CDCBF4Q39035931-B427E051-2F62-4E1F-B4AE-4952C389ED5AQ39042940-B8A8335D-843F-451C-A144-357FBD464627Q40081220-436E8273-96B3-4890-9CF3-3AF9A8A05D34Q40985577-3D060111-D31B-4F62-88C1-98463629DC88Q42058488-FD7314ED-724A-4875-BDD7-13E04440A50CQ45589559-46ACAB49-2591-40DC-A8C9-8829DA0A6284Q45869248-7CF411C3-F092-4BE7-A909-5936EB05D195Q47191569-9CCB0834-B578-4EE5-9020-791ACEF6041EQ53700837-B48ACF50-EE47-47B6-80CD-6153565B2D36Q54013327-A0666DD7-F0A0-4817-9897-38FACABA0805
P2860
The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The effect of antidrug antibod ...... ritis: practical consequences.
@en
type
label
The effect of antidrug antibod ...... ritis: practical consequences.
@en
prefLabel
The effect of antidrug antibod ...... ritis: practical consequences.
@en
P2093
P2860
P1476
The effect of antidrug antibod ...... ritis: practical consequences.
@en
P2093
Catalin Codreanu
Eduardo Mysler
Francisco Briceño
Mauro Keiserman
Rohini Handa
Servet Akar
P2860
P304
P356
10.1586/1744666X.2014.926219
P577
2014-06-25T00:00:00Z